PTC Positive Results, Regulatory Update for Vatiquinone Friedreich Ataxia Program

  Statistically significant results on primary endpoint of long-term study analyses -

- Following FDA pre-NDA feedback, submission on track for December 2024 -

https://www.prnewswire.com/news-releases/ptc-therapeutics-announces-positive-results-from-long-term-treatment-studies-and-updates-on-regulatory-progress-for-vatiquinone-friedreich-ataxia-program-302269891.html